Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2129 in Patients With Knee Osteoarthritis
NCT07351968Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-2129 in knee osteoarthritis (OA) (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score at 4 weeks. Started Mar 2026; status: completed.
02
Drugs
HRS-2129
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07351968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351968.